Browsing Tag
MCO-010
2 posts
Can Nanoscope make severe retinitis pigmentosa treatable without knowing the mutation?
The FDA has accepted Nanoscope Therapeutics’ BLA for MOGENRY, a one-time optogenetic therapy designed to restore useful vision in severe retinitis pigmentosa regardless of the patient’s underlying mutation.
Nanoscope moves mutation-agnostic MOGENRY gene therapy into FDA review
The FDA has accepted Nanoscope Therapeutics’ MOGENRY BLA for severe-vision-loss retinitis pigmentosa, moving a one-time optogenetic treatment toward potential approval without requiring mutation-specific genetic targeting.